Reducing biologic doses for chronic sinusitis with polyps
Part of Ear, nose & throat, Immune system & allergy clinical trials.
This trial tests if patients with chronic sinusitis and nasal polyps can safely reduce how often they take their biologic medication (dupilumab or mepolizumab) after their disease has been partly controlled for at least a year.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You are currently taking dupilumab or mepolizumab every 4 weeks.
- You have been on the same dose schedule for at least 3 months.
- For at least 1 year on biologics, your sinusitis symptoms have been 'partly controlled' (like having some blockage, mucus, or smell loss most days, but not severe).
- You do not have a cancer that would prevent you from joining.
- You can understand Danish and give informed consent.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether combining mepolizumab (a biologic injection) with a quick in-office removal of nasal polyps improves symptoms better than usual care. It is for adults with chronic sinusitis and nasal polyps who qualify for biologic therapy.
This study looks at how “biologic” medicines work in real-life care for people with severe chronic rhinosinusitis with nasal polyps (CRSwNP). It may help confirm which patients benefit and how treatment is used in everyday practice.
This study tests whether dupilumab, a medication given as an injection, helps improve the lining of the nose in people with chronic sinus inflammation and nasal polyps. If you have nasal polyps and are about to start dupilumab, or if you have sinusitis without polyps, you may be eligible to join.
This study looks at blood and other measures (biomarkers) to understand how well mepolizumab helps people with nasal polyps, with or without asthma. It aims to find response clues that could help personalize treatment in the future.
This study looks at patients with nasal polyps and chronic sinusitis who have been stable on a biologic medicine (Dupilumab or Mepolizumab) for at least 3 months. It checks if they stay in remission (symptoms well controlled, no need for extra treatments) for a full year.
This study follows patients in France who are receiving biologic treatments for severe nasal polyps with chronic sinusitis. It collects information on how well these treatments work and their side effects over time.
Hear when a new Chronic Rhinosinusitis With Nasal Polyps trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.